University Home | Hospital | Pulse Employment | Contact Us | Search | News 
Thomas Jefferson University Search Jefferson
Jefferson Medical College Jefferson College of Graduate Studies Jefferson College of Health Professions
Menu
Thomas Jefferson University - Hallgeir Rui, MD, PhD
Hallgeir Rui, MD, PhD

Cancer Biology
Thomas Jefferson University
Jefferson Medical College
Professor of Cancer Biology
Professor of Medical Oncology
Professor of Pathology
Scientific Director, Jefferson Breast Care Ctr
Program Leader, Biology of Breast Cancer
Kimmel Cancer Center at Jefferson
Co-Director, Translational Research Core
Appointed: 2006
Mailing Address
233 S 10th St, BLSB 330
Philadelphia, Pennsylvania 19107
United States
Contact Information
Phone: 215-503-9259
Fax: 215-503-9246
Hallgeir.Rui@jefferson.edu
Personal Web Site
Qualifications
M.D. University of Oslo, Oslo, Norway, 1987
Ph.D. Pathology, University of Oslo, Norway 1988
Expertise and Research Interests
Dr. Rui has made a series of contributions to increased understanding of the molecular mechanisms of signal transduction by receptors for prolactin and related cytokines and hormones. Dr. Rui was the first to isolate a prolactin receptor-associated tyrosine kinase, and to identify this molecule as Janus kinase-2. Dr. Rui's laboratory has maintained a focus on prolactin receptor function with a primary goal of understanding the role of downstream Jak-Stat pathways and their aberrations in breast cancer.

Activation of Stat5 is a strong favorable prognostic marker in breast cancer and an invasion-suppressive role of Stat5 in human breast cancer may represent a biological mechanism. Loss of Stat5 is further associated with increased risk of antiestrogen resistance. Dr. Rui and his team have also invented and applied a new technology to generate high density tumor tissue arrays for high-through-put molecular profiling. Dr. Rui is the PI of a $6.7 million, 5 year Komen Promise Grant to a consortium of multidisciplinary investigators to classify malignant breast tumors based on expression of druggable target proteins for improved personalized cancer care. The consortium project also involves a novel Bayesian adaptive biomarker-centered Phase II clinical trial of a Parp-inhibitor in the neoadjuvant setting for triple-negative breast cancer.
Keywords
cancer; breast cancer; hormone; endocrinology; prolactin; growth hormone; estrogen; glucocorticoid; steroid hormones; Jak2; Stat5; Stat5a; Stat5b; immunohistochemistry; pathology; biomarker; early detection; microarray; tissue microarray; mouse modeling; EGFR; Her2; ErbB2; prolactin receptor;
Publications

Individual Expertise profile of Hallgeir Rui, MD, PhD, Copyright © Hallgeir Rui, MD, PhD.
Last Updated by Hallgeir Rui, MD, PhD : Thursday, August 9, 2012 9:45:18 AM



 Printable Version

Thomas Jefferson University
Thomas Jefferson University